David Hook has joined New Haven, Connecticut-based Biorez Inc. as its vice president of sales.
David Hook Joins Biorez as VP of Sales
Hook has over 20 years of worldwide medical device experience. For 16 years he worked at Mitek Sports Medicine (part of the DePuy Synthes Companies of Johnson & Johnson) where he advanced from sales representative to worldwide director of professional education and market development. Since then, Hook has worked in leadership roles as director of market development at Conventus Orthopaedics, Trice Medical, and Rotation Medical. His most recent position before joining Biorez was as vice president of sales at Xiros North America.
Biorez Founder and CEO Kevin Rocco expressed excitement about Hook joining the company: “David [Hook] is a talented commercial executive with extensive relationships and experience launching new disruptive technologies in sports medicine, and we are excited to welcome him to our team.”
Rocco continued, “David [Hook] was also a key member of Rotation Medical, where he drove market adoption and clinical education of their regenerative implant for rotator cuff repair, from the first surgical case post-FDA clearance through a successful acquisition by Smith & Nephew.”
Founded in 2016, Biorez is focused on treatments for tendon and ligament injuries. Its flagship product is the BioBrace™ Implant. Per its website, the BioBrace Implant is a “bioinductive scaffold that is intended to reinforce soft tissue where weakness exists, and promote soft tissue healing.” It can be used for “reinforcement of soft tissues that are repaired by suture or suture anchors, during tendon repair surgery.” Last month, it received FDA 510(k) clearance.
Hook remarked, “Implants that are bioinductive while providing structure for healing tissues during the repair or reconstruction continuum is the natural progression with this type of technology and I am looking forward to working with our surgeons to deliver the best-in-class implant for their practice and their patients.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.